Glecaprevir (BioDeep_00000798977)
代谢物信息卡片
Glecaprevir
化学式: C38H46F4N6O9S (838.2983)
中文名称: 格卡瑞韦
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC1(CC1)S(=O)(=O)NC(=O)C2(CC2C(F)F)NC(=O)C3CC4CN3C(=O)C(NC(=O)OC5CCCC5OCC=CC(C6=NC7=CC=CC=C7N=C6O4)(F)F)C(C)(C)C
InChI: InChI=1S/C38H46F4N6O9S/c1-35(2,3)28-32(50)48-19-20(17-24(48)30(49)46-37(18-21(37)29(39)40)33(51)47-58(53,54)36(4)14-15-36)56-31-27(43-22-9-5-6-10-23(22)44-31)38(41,42)13-8-16-55-25-11-7-12-26(25)57-34(52)45-28/h5-6,8-10,13,20-21,24-26,28-29H,7,11-12,14-19H2,1-4H3,(H,45,52)(H,46,49)(H,47,51)/b13-8+/t20-,21+,24+,25-,26-,28-,37-/m1/s1
描述信息
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams
C254 - Anti-Infective Agent > C281 - Antiviral Agent
同义名列表
1 个代谢物同义名
数据库引用编号
6 个数据库交叉引用编号
- KEGGdrug: D10814
- PubChem: 66828839
- DrugBank: DB13879
- ChEMBL: CHEMBL3545363
- CAS: 1838571-99-5
- CAS: 1365970-03-1
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
| 亚细胞结构定位 | 关联基因列表 |
|---|
文献列表
- Jyh-Jou Chen, Yen-Cheng Chiu, Pei-Lun Lee, Hung-Da Tung, Hung-Chih Chiu, Shih-Chieh Chien, Pin-Nan Cheng. Real-world effectiveness and safety of sofosbuvir/velpatasvir and glecaprevir/pibrentasvir for genotype 6 chronic hepatitis C.
Journal of the Formosan Medical Association = Taiwan yi zhi.
2022 Nov; 121(11):2265-2272. doi:
10.1016/j.jfma.2022.04.020. [PMID: 35581112] - Takeshi Hatanaka, Satoru Kakizaki, Takuya Kaburagi, Naoto Saito, Sachi Nakano, Yoichi Hazama, Sachiko Yoshida, Yoko Hachisu, Yoshiki Tanaka, Teruo Yoshinaga, Kenji Kashiwabara, Atsushi Naganuma, Yuichi Yamazaki, Toshio Uraoka, Shigeo Nagashima, Masaharu Takahashi, Tsutomu Nishizawa, Kazumoto Murata, Hiroaki Okamoto. Chronic Infection with Hepatitis C Virus Subtype 1g in a Japanese Patient Successfully Treated with Glecaprevir/Pibrentasvir.
Internal medicine (Tokyo, Japan).
2022 May; 61(10):1537-1543. doi:
10.2169/internalmedicine.8673-21. [PMID: 34897154] - Michelle T Martin, Nicole Waring, Ammara Naveed. High Real-World Sustained Virologic Response Rate with Glecaprevir/Pibrentasvir at a Racially Diverse Urban Academic Medical Center.
Gut and liver.
2022 05; 16(3):489-492. doi:
10.5009/gnl210499. [PMID: 35145046] - Lone W Madsen, Peer B Christensen, Janne F Hansen, Birgit T Røge, Dorte K Holm, Sandra Dröse, Anne Øvrehus. Four Weeks Treatment with Glecaprevir/Pibrentasvir + Ribavirin-A Randomized Controlled Clinical Trial.
Viruses.
2022 03; 14(3):. doi:
10.3390/v14030614. [PMID: 35337021] - Akari Kaba, Shigeyoshi Yamanaga, Yuji Hidaka, Mariko Toyoda, Masayuki Kashima, Yoshi Takekuma, Akito Inadome, Hiroshi Yokomizo, Akira Miyata. Glecaprevir/Pibrentasvir and Renal Dysfunction in Deceased Donor Renal Transplantation: A Case Report.
Transplantation proceedings.
2022 Mar; 54(2):549-551. doi:
10.1016/j.transproceed.2021.12.028. [PMID: 35120765] - Kerstin Stein, Albrecht Stoehr, Hartwig Klinker, Gerlinde Teuber, Uwe Naumann, Christine John, Renate Heyne, Yvonne Serfert, Claus Niederau, Stefan Zeuzem, Thomas Berg, Johannes Wiegand. Hepatitis C therapy with grazoprevir/elbasvir and glecaprevir/pibrentasvir in patients with advanced chronic kidney disease: data from the German Hepatitis C-Registry (DHC-R).
European journal of gastroenterology & hepatology.
2022 01; 34(1):76-83. doi:
10.1097/meg.0000000000001923. [PMID: 32956186] - Noriyuki Akutsu, Shigeru Sasaki, Takeshi Matsui, Hirofumi Akashi, Kazuhiko Yonezawa, Keisuke Ishigami, Masayuki Tsujisaki, Hiroyuki Isshiki, Atsushi Yawata, Satoshi Yamaoka, Toshihiro Ban, Takeya Adachi, Seiya Nakahara, Hideyasu Takagi, Kohei Nakachi, Katsunori Tanaka, Takehiro Hirano, Itaru Yamamoto, Hiroyuki Kaneto, Kohei Wagatsuma, Yasunao Numata, Hiroshi Nakase. Association of the Low-density Lipoprotein Cholesterol/High-density Lipoprotein Cholesterol Ratio with Glecaprevir-pibrentasvir Treatment.
Internal medicine (Tokyo, Japan).
2021 Nov; 60(21):3369-3376. doi:
10.2169/internalmedicine.7098-21. [PMID: 34024854] - Daryl U Nnani, Alesa Campbell, Maria Ajaimy, Omar Saeed, Snehal R Patel, Sana Ahmed, Jay A Graham, Ulrich P Jorde. Effect of glecaprevir/pibrentasvir on weight-adjusted tacrolimus trough/dose ratios in heart and kidney transplant recipients.
Transplant infectious disease : an official journal of the Transplantation Society.
2021 Oct; 23(5):e13716. doi:
10.1111/tid.13716. [PMID: 34407270] - Tasuku Hara, Tomoya Ohara, Masashi Taniguchi, Hiroaki Sakai, Kohei Oka, Naoto Iwai, Toshifumi Tsuji, Takashi Okuda, Akihiro Nagata, Toshiyuki Komaki, Junichi Sakagami, Keizo Kagawa. Severe Liver Injury Associated with Glecaprevir Plus Pibrentasvir Therapy in a Patient with Treatment-naïve Hepatitis C Virus Infection.
Internal medicine (Tokyo, Japan).
2021 Aug; 60(15):2437-2443. doi:
10.2169/internalmedicine.6664-20. [PMID: 33612683] - Young Joo Park, Hyun Young Woo, Jeong Heo, Sang Gyu Park, Young Mi Hong, Ki Tae Yoon, Dong Uk Kim, Gwang Ha Kim, Hyung Hoi Kim, Geun Am Song, Mong Cho. Real-Life Effectiveness and Safety of Glecaprevir/Pibrentasvir for Korean Patients with Chronic Hepatitis C at a Single Institution.
Gut and liver.
2021 05; 15(3):440-450. doi:
10.5009/gnl19393. [PMID: 32839365] - Meghan E Sise, David S Goldberg, Jens J Kort, Douglas E Schaubel, Rita R Alloway, Christine M Durand, Robert J Fontana, Robert S Brown, John J Friedewald, Stacey Prenner, J Richard Landis, Melissa Fernando, Caitlin C Phillips, E Steve Woodle, Adele Rike-Shields, Kenneth E Sherman, Nahel Elias, Winfred W Williams, Jenna L Gustafson, Niraj M Desai, Brittany Barnaba, Silas P Norman, Mona Doshi, Samuel T Sultan, Meredith J Aull, Josh Levitsky, Dianne S Belshe, Raymond T Chung, Peter P Reese. Multicenter Study to Transplant Hepatitis C-Infected Kidneys (MYTHIC): An Open-Label Study of Combined Glecaprevir and Pibrentasvir to Treat Recipients of Transplanted Kidneys from Deceased Donors with Hepatitis C Virus Infection.
Journal of the American Society of Nephrology : JASN.
2020 11; 31(11):2678-2687. doi:
10.1681/asn.2020050686. [PMID: 32843477] - Wei-Ming Chen, Kuo-Liang Wei, Shui-Yi Tung, Chien-Heng Shen, Te-Sheng Chang, Chih-Wei Yen, Yung-Yu Hsieh, Wen Nan Chiu, Jin Hung Hu, Sheng-Nan Lu, Chao-Hung Hung. High viral load predicts virologic failure in chronic genotype 2 hepatitis C virus-infected patients receiving glecaprevir/pibrentasvir therapy.
Journal of the Formosan Medical Association = Taiwan yi zhi.
2020 Nov; 119(11):1593-1600. doi:
10.1016/j.jfma.2020.08.010. [PMID: 32839045] - Paul Kwo, Deepti Dronamraju. More evidence that direct acting antiviral therapy is safe and effective in cirrhosis and chronic kidney disease including peritoneal dialysis.
Clinical and molecular hepatology.
2020 10; 26(4):489-491. doi:
10.3350/cmh.2020.0228. [PMID: 32967407] - Satoshi Takakusagi, Hitoshi Takagi, Yozo Yokoyama, Kyoko Marubashi, Kazuko Kizawa, Takashi Kosone, Ken Sato, Satoru Kakizaki, Toshio Uraoka. Successful treatment with glecaprevir/pibrentasvir for chronic hepatitis C complicated by primary biliary cholangitis.
Clinical journal of gastroenterology.
2020 Oct; 13(5):896-901. doi:
10.1007/s12328-020-01103-w. [PMID: 32065362] - Rajneet K Oberoi, Weihan Zhao, Matthew Rosebraugh, Federico Mensa, Haoyu Wang, Wei Liu. A Thorough QT Study of the Combination Glecaprevir + Pibrentasvir on Cardiac Repolarization in Healthy Subjects.
Clinical therapeutics.
2020 07; 42(7):1317-1329. doi:
10.1016/j.clinthera.2020.05.009. [PMID: 32622784] - Anas Shamsi, Taj Mohammad, Saleha Anwar, Mohamed F AlAjmi, Afzal Hussain, Md Tabish Rehman, Asimul Islam, Md Imtaiyaz Hassan. Glecaprevir and Maraviroc are high-affinity inhibitors of SARS-CoV-2 main protease: possible implication in COVID-19 therapy.
Bioscience reports.
2020 06; 40(6):. doi:
10.1042/bsr20201256. [PMID: 32441299] - Chen-Hua Liu, Sheng-Shun Yang, Cheng-Yuan Peng, Woan-Tyy Lin, Chun-Jen Liu, Tung-Hung Su, Tai-Chung Tseng, Pei-Jer Chen, Ding-Shinn Chen, Jia-Horng Kao. Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection and severe renal impairment.
Journal of viral hepatitis.
2020 06; 27(6):568-575. doi:
10.1111/jvh.13265. [PMID: 31981264] - Akiyoshi Kinoshita, Kazuhiko Koike, Yusuke Mizuno, Itsuro Ogata, Yutaro Kobayashi, Kiyoshi Hasegawa, Koichi Shiraishi, Hideo Yoshida, Ryo Nakata, Norie Yamada, Kiyomi Yasuda. Efficacy and safety of glecaprevir/pibrentasvir in patients with hepatitis C virus infection aged ≥75 years.
Geriatrics & gerontology international.
2020 Jun; 20(6):578-583. doi:
10.1111/ggi.13919. [PMID: 32267087] - Eric Lawitz, Robert Flisiak, Manal Abunimeh, Meghan E Sise, Jun Y Park, Marwan Kaskas, Annette Bruchfeld, Marcus-Alexander Wörns, Andrea Aglitti, Philippe J Zamor, Zhenyi Xue, Gretja Schnell, Yash J Jalundhwala, Ariel Porcalla, Federico J Mensa, Marcello Persico. Efficacy and safety of glecaprevir/pibrentasvir in renally impaired patients with chronic HCV infection.
Liver international : official journal of the International Association for the Study of the Liver.
2020 05; 40(5):1032-1041. doi:
10.1111/liv.14320. [PMID: 31821716] - Ahmed Abbas Suleiman, Chih-Wei Lin, Wei Liu, Doerthe Eckert, Sven Mensing, Margaret Burroughs, Koji Kato, Kazuaki Chayama, Hiromitsu Kumada, Rajneet K Oberoi. Population Pharmacokinetics of Glecaprevir/Pibrentasvir in HCV-infected Japanese Subjects in Phase 3 CERTAIN-1 and CERTAIN-2 Trials.
Journal of clinical pharmacology.
2020 03; 60(3):331-339. doi:
10.1002/jcph.1524. [PMID: 31515816] - Jamie Huff, Rebecca Andersen. Glecaprevir/Pibrentasvir: The First 8-Week, Pangenotypic HCV Treatment Regimen for Patients 12 Years of Age and Older.
The Annals of pharmacotherapy.
2020 03; 54(3):262-276. doi:
10.1177/1060028019877128. [PMID: 31537106] - Hsu-Heng Yen, Pei-Yuan Su, Ya-Huei Zeng, I-Ling Liu, Siou-Ping Huang, Yu-Chun Hsu, Yang-Yuan Chen, Chia-Wei Yang, Shun-Sheng Wu, Kun-Ching Chou. Glecaprevir-pibrentasvir for chronic hepatitis C: Comparing treatment effect in patients with and without end-stage renal disease in a real-world setting.
PloS one.
2020; 15(8):e0237582. doi:
10.1371/journal.pone.0237582. [PMID: 32790715] - Robert J Fontana, Sabela Lens, Stuart McPherson, Magdy Elkhashab, Victor Ankoma-Sey, Mark Bondin, Ana Gabriela Pires Dos Santos, Zhenyi Xue, Roger Trinh, Ariel Porcalla, Stefan Zeuzem. Efficacy and Safety of 8 Weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve, HCV-Infected Patients with APRI ≤ 1 in a Single-Arm, Open-Label, Multicenter Study.
Advances in therapy.
2019 12; 36(12):3458-3470. doi:
10.1007/s12325-019-01123-0. [PMID: 31646465] - Edward Gane, Fred Poordad, Neddie Zadeikis, Joaquin Valdes, Chih-Wei Lin, Wei Liu, Armen Asatryan, Stanley Wang, Catherine Stedman, Susan Greenbloom, Tuan Nguyen, Magdy Elkhashab, Marcus-Alexander Wörns, Albert Tran, Jean-Pierre Mulkay, Carolyn Setze, Yao Yu, Tami Pilot-Matias, Ariel Porcalla, Federico J Mensa. Safety and Pharmacokinetics of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1-6 Hepatitis C Virus Infections and Compensated Liver Disease.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
2019 10; 69(10):1657-1664. doi:
10.1093/cid/ciz022. [PMID: 30923816] - Marcello Persico, Andrea Aglitti, Michele Milella, Carmine Coppola, Vincenzo Messina, Ernesto Claar, Ivan Gentile, Fernando Sogari, Paola Pierri, Lorenzo A Surace, Filomena Morisco, Paolo Tundo, Giuseppina Brancaccio, Gaetano Serviddio, Pietro Gatti, Antonio P Termite, Giovan G Di Costanzo, Benedetto Caroleo, Raffaele Cozzolongo, Nicola Coppola, Annamaria Longo, Luca Fontanella, Alessandro Federico, Valerio Rosato, Irene Terrenato, Mario Masarone. Real-life glecaprevir/pibrentasvir in a large cohort of patients with hepatitis C virus infection: The MISTRAL study.
Liver international : official journal of the International Association for the Study of the Liver.
2019 10; 39(10):1852-1859. doi:
10.1111/liv.14170. [PMID: 31175707] - Antonio Franco, Francesc Moreso, Esperanza Merino, Asunción Sancho, Julia Kanter, Adelina Gimeno, Noelia Balibrea, Maria Rodriguez, Francisco Perez Contreras. Renal transplantation from seropositive hepatitis C virus donors to seronegative recipients in Spain: a prospective study.
Transplant international : official journal of the European Society for Organ Transplantation.
2019 Jul; 32(7):710-716. doi:
10.1111/tri.13410. [PMID: 30773693] - Takahiro Shinzato, Taro Kubo, Toshihiro Shimizu, Koji Nanmoku, Takashi Yagisawa. Fibrosing cholestatic hepatitis in a kidney transplant recipient with hepatitis C virus.
CEN case reports.
2019 05; 8(2):101-105. doi:
10.1007/s13730-018-0374-6. [PMID: 30604247] - Masanori Atsukawa, Akihito Tsubota, Hidenori Toyoda, Koichi Takaguchi, Makoto Nakamuta, Tsunamasa Watanabe, Kojiro Michitaka, Tadashi Ikegami, Akito Nozaki, Haruki Uojima, Shinya Fukunishi, Takuya Genda, Hiroshi Abe, Naoki Hotta, Kunihiko Tsuji, Chikara Ogawa, Yoshihiko Tachi, Toshihide Shima, Noritomo Shimada, Chisa Kondo, Takehiro Akahane, Yoshio Aizawa, Yasuhito Tanaka, Takashi Kumada, Katsuhiko Iwakiri. The efficacy and safety of glecaprevir plus pibrentasvir in 141 patients with severe renal impairment: a prospective, multicenter study.
Alimentary pharmacology & therapeutics.
2019 05; 49(9):1230-1241. doi:
10.1111/apt.15218. [PMID: 30873651] - Roberta D'Ambrosio, Luisa Pasulo, Massimo Puoti, Maria Vinci, Monica Schiavini, Sergio Lazzaroni, Alessandro Soria, Federico Gatti, Barbara Menzaghi, Alessio Aghemo, Francesca Capelli, Maria Grazia Rumi, Lorenzo Morini, Alessia Giorgini, Marie Graciella Pigozzi, Angelo Rossini, Franco Maggiolo, Angelo Pan, Massimo Memoli, Ombretta Spinelli, Paolo Del Poggio, Valeria Saladino, Angiola Spinetti, Anna De Bona, Andrea Capretti, Caterina Uberti-Foppa, Paolo Bonfanti, Natalia Terreni, Fernanda Menozzi, Alberto Eraldo Colombo, Omar Giglio, Riccardo Centenaro, Marta Borghi, Chiara Baiguera, Viviana Picciotto, Simona Landonio, Andrea Gori, Carlo Magnani, Franco Noventa, Stefania Paolucci, Pietro Lampertico, Stefano Fagiuoli. Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C.
Journal of hepatology.
2019 03; 70(3):379-387. doi:
10.1016/j.jhep.2018.11.011. [PMID: 30472321] - Tatsuo Kanda, George K K Lau, Lai Wei, Mitsuhiko Moriyama, Ming-Lung Yu, Wang-Long Chuang, Alaaeldin Ibrahim, Cosmas Rinaldi Adithya Lesmana, Jose Sollano, Manoj Kumar, Ankur Jindal, Barjesh Chander Sharma, Saeed S Hamid, A Kadir Dokmeci, Mamun-Al-Mahtab, Geofferey W McCaughan, Jafri Wasim, Darrell H G Crawford, Jia-Horng Kao, Osamu Yokosuka, Shiv Kumar Sarin, Masao Omata. APASL clinical practice recommendation: how to treat HCV-infected patients with renal impairment?.
Hepatology international.
2019 Mar; 13(2):103-109. doi:
10.1007/s12072-018-9915-5. [PMID: 30539517] - Matthew P Kosloski, Haoyu Wang, David Pugatch, Federico J Mensa, Edward Gane, Eric Lawitz, Thomas C Marbury, Richard A Preston, Jens Kort, Wei Liu. Pharmacokinetics and safety of glecaprevir and pibrentasvir in HCV-negative subjects with hepatic impairment.
European journal of clinical pharmacology.
2019 Feb; 75(2):217-226. doi:
10.1007/s00228-018-2576-4. [PMID: 30341499] - Graham R Foster, Tarik Asselah, Sarah Kopecky-Bromberg, Yang Lei, Armen Asatryan, Roger Trinh, Neddie Zadeikis, Federico J Mensa. Safety and efficacy of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C in patients aged 65 years or older.
PloS one.
2019; 14(1):e0208506. doi:
10.1371/journal.pone.0208506. [PMID: 30601818] - Graham R Foster, Gregory J Dore, Stanley Wang, Jason Grebely, Kenneth E Sherman, Axel Baumgarten, Brian Conway, Daniel Jackson, Tarik Asselah, Michael Gschwantler, Krzysztof Tomasiewicz, Humberto Aguilar, Armen Asatryan, Yiran Hu, Federico J Mensa. Glecaprevir/pibrentasvir in patients with chronic HCV and recent drug use: An integrated analysis of 7 phase III studies.
Drug and alcohol dependence.
2019 01; 194(?):487-494. doi:
10.1016/j.drugalcdep.2018.11.007. [PMID: 30529905] - Brian L Pearlman, Andrew E Hinds. Review article: novel antivirals for hepatitis C-sofosbuvir/velpatasvir/voxilaprevir, glecaprevir/pibrentasvir.
Alimentary pharmacology & therapeutics.
2018 11; 48(9):914-923. doi:
10.1111/apt.14977. [PMID: 30288771] - Fabrizio Fabrizi, Piergiorgio Messa. Managing hepatitis C therapy failures and chronic kidney disease.
Expert review of clinical pharmacology.
2018 Nov; 11(11):1135-1142. doi:
10.1080/17512433.2018.1534202. [PMID: 30309263] - Nancy Reau, Paul Y Kwo, Susan Rhee, Robert S Brown, Kosh Agarwal, Peter Angus, Edward Gane, Jia-Horng Kao, Parvez S Mantry, David Mutimer, K Rajender Reddy, Tram T Tran, Yiran B Hu, Abhishek Gulati, Preethi Krishnan, Emily O Dumas, Ariel Porcalla, Nancy S Shulman, Wei Liu, Suvajit Samanta, Roger Trinh, Xavier Forns. Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection.
Hepatology (Baltimore, Md.).
2018 10; 68(4):1298-1307. doi:
10.1002/hep.30046. [PMID: 29672891] - Deirdre Sawinski, Kimberly A Forde, Christina M Wyatt. New Treatment Options for Hepatitis C Virus Infection in End-Stage Kidney Disease: To Treat or Not to Treat.
American journal of kidney diseases : the official journal of the National Kidney Foundation.
2018 07; 72(1):7-9. doi:
10.1053/j.ajkd.2018.01.049. [PMID: 29580661] - Yuji Teraoka, Takuro Uchida, Michio Imamura, Mitsutaka Osawa, Masataka Tsuge, Hiromi Abe-Chayama, C Nelson Hayes, Grace Naswa Makokha, Hiroshi Aikata, Daiki Miki, Hidenori Ochi, Yuji Ishida, Chise Tateno, Kazuaki Chayama. Prevalence of NS5A resistance associated variants in NS5A inhibitor treatment failures and an effective treatment for NS5A-P32 deleted hepatitis C virus in humanized mice.
Biochemical and biophysical research communications.
2018 06; 500(2):152-157. doi:
10.1016/j.bbrc.2018.04.005. [PMID: 29621544] - Ameer Abutaleb, Shyam Kottilil, Eleanor Wilson. Glecaprevir/pibrentasvir expands reach while reducing cost and duration of hepatitis C virus therapy.
Hepatology international.
2018 May; 12(3):214-222. doi:
10.1007/s12072-018-9873-y. [PMID: 29845496] - Andres F Carrion, Paul Martin. Glecaprevir + pibrentasvir for treatment of hepatitis C.
Expert opinion on pharmacotherapy.
2018 Mar; 19(4):413-419. doi:
10.1080/14656566.2018.1444030. [PMID: 29465262] - Matthew P Kosloski, Weihan Zhao, Thomas C Marbury, Richard A Preston, Michael G Collins, David Pugatch, Federico Mensa, Jens Kort, Wei Liu. Effects of Renal Impairment and Hemodialysis on the Pharmacokinetics and Safety of the Glecaprevir and Pibrentasvir Combination in Hepatitis C Virus-Negative Subjects.
Antimicrobial agents and chemotherapy.
2018 03; 62(3):. doi:
10.1128/aac.01990-17. [PMID: 29263061] - Chih-Wei Lin, Sandeep Dutta, Weihan Zhao, Armen Asatryan, Andrew Campbell, Wei Liu. Pharmacokinetic Interactions and Safety of Coadministration of Glecaprevir and Pibrentasvir in Healthy Volunteers.
European journal of drug metabolism and pharmacokinetics.
2018 Feb; 43(1):81-90. doi:
10.1007/s13318-017-0428-8. [PMID: 28688001] - Fabrizio Fabrizi, Francesco Negro, Mark Bondin, Patrice Cacoub. Expert opinion on the management of renal manifestations of chronic HCV infection.
Antiviral therapy.
2018; 23(Suppl 2):57-67. doi:
10.3851/imp3247. [PMID: 30451153] - Edward Gane, Eric Lawitz, David Pugatch, Georgios Papatheodoridis, Norbert Bräu, Ashley Brown, Stanislas Pol, Vincent Leroy, Marcello Persico, Christophe Moreno, Massimo Colombo, Eric M Yoshida, David R Nelson, Christine Collins, Yang Lei, Matthew Kosloski, Federico J Mensa. Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment.
The New England journal of medicine.
2017 10; 377(15):1448-1455. doi:
10.1056/nejmoa1704053. [PMID: 29020583] - Matthew P Kosloski, Weihan Zhao, Armen Asatryan, Jens Kort, Pierre Geoffroy, Wei Liu. No Clinically Relevant Drug-Drug Interactions between Methadone or Buprenorphine-Naloxone and Antiviral Combination Glecaprevir and Pibrentasvir.
Antimicrobial agents and chemotherapy.
2017 10; 61(10):. doi:
10.1128/aac.00958-17. [PMID: 28807904]
